Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Journal of the National Comprehensive Cancer Network : JNCCN - Tập 18 Số 10 - Trang 1385-1415 - 2020

Michael W. Deininger¹, Neil P. Shah², Jessica K. Altman³, Ellin Berman⁴, Ravi Bhatia⁵, Bhavana Bhatnagar⁶, Daniel J. DeAngelo⁷, Jason Gotlib⁸, Gabriela Hobbs^9,10, Lori J. Maness¹¹, Monica Mead¹², Leland Metheny¹³, Sanjay Mohan¹¹, Joseph O. Moore¹⁴, Kiran Naqvi¹⁵, Vivian G. Oehler¹⁶, Arnel Pallera¹⁷, Mrinal M. Patnaik¹⁸, Keith W. Pratz¹⁹, Iskra Pusic²⁰, Michal G. Rose²¹, B. Douglas Smith²², David S. Snyder²³, Kendra Sweet²⁴, Moshe Talpaz^25,26, James E. Thompson¹¹, David T. Yang²⁷, Kristina M. Gregory²⁸, Hema Sundar²⁸

¹1Huntsman Cancer Institute at the University of Utah;

²2UCSF Helen Diller Family Comprehensive Cancer Center;

³3Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

⁴4Memorial Sloan Kettering Cancer Center;

⁵5O'Neal Comprehensive Cancer Center at UAB;

⁶6The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

⁷7Dana-Farber/Brigham and Women’s Cancer Center;

⁸8Stanford Cancer Institute;

⁹Massachusetts General Hospital Cancer Center; 10 Fred and

¹⁰Pamela Buffett Cancer Center;

¹¹ The Ohio State University Comprehensive Cancer Center -James Cancer Hospital and Solove Research Institute;

¹²11UCLA Jonsson Comprehensive Cancer Center;

¹³Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; 13 Vanderbilt-Ingram Cancer Center;

¹⁴14Duke Cancer Institute;

¹⁵15The University of Texas MD Anderson Cancer Center;

¹⁶16Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

¹⁷17St. Jude Children's Research Hospital/The University of Tennessee Health Science Center;

¹⁸18Mayo Clinic Cancer Center;

¹⁹19Abramson Cancer Center at the University of Pennsylvania;

²⁰20Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

²¹21Yale Cancer Center/Smilow Cancer Hospital;

²²22The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

²³23City of Hope National Medical Center;

²⁴24Moffitt Cancer Center;

²⁵Comprehensive Cancer Center,

²⁶University of Michigan Rogel Cancer Center; 26 Roswell Park

²⁷27University of Wisconsin Carbone Cancer Center; and

²⁸28National Comprehensive Cancer Network

Tóm tắt

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to aBCR-ABL1fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase CML.

Từ khóa

Tài liệu tham khảo

Müller, 2009, Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations, Blood, 114, 4944, 10.1182/blood-2009-04-214221

Dorer, 2016, Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients, Leuk Res, 48, 84, 10.1016/j.leukres.2016.07.007

Aleem, 2009, Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia, Hematol Oncol Stem Cell Ther, 2, 358, 10.1016/S1658-3876(09)50026-X

Seymour, 2014, A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia, Blood Cancer J, 4, e238, 10.1038/bcj.2014.60

Pfirrmann, 2016, Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia, Leukemia, 30, 48, 10.1038/leu.2015.261

Verstovsek, 2002, Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course, Cancer, 94, 2416, 10.1002/cncr.10490

Guérin, 2014, Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase, Curr Med Res Opin, 30, 1345, 10.1185/03007995.2014.904281

Rea, 2017, Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study, Blood, 129, 846, 10.1182/blood-2016-09-742205

Marin, 2008, European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor, Blood, 112, 4437, 10.1182/blood-2008-06-162388

Kantarjian, 2011, Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy, J Clin Oncol, 29, 1512, 10.1200/JCO.2010.33.9176

Osorio, 2018, Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?, Ann Hematol, 97, 2089, 10.1007/s00277-018-3413-7

Gambacorti-Passerini, 2018, Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study, Haematologica, 103, 1298, 10.3324/haematol.2017.171249

Khorashad, 2013, BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships, Blood, 121, 489, 10.1182/blood-2012-05-431379

Hegedus, 2009, Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties, Br J Pharmacol, 158, 1153, 10.1111/j.1476-5381.2009.00383.x

Biernaux, 1995, Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals, Blood, 86, 3118, 10.1182/blood.V86.8.3118.3118

Annunziata, 2020, Current strategies and future directions to achieve deep molecular response and treatment-free remission in chronic myeloid leukemia, Front Oncol, 10, 883, 10.3389/fonc.2020.00883

Al Bahar, 2004, Pregnancy in chronic myeloid leukemia patients treated with alpha interferon, Int J Gynaecol Obstet, 85, 281, 10.1016/j.ijgo.2003.11.014

Mori, 2015, Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study, Am J Hematol, 90, 910, 10.1002/ajh.24120

Druker, 2006, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia, N Engl J Med, 355, 2408, 10.1056/NEJMoa062867

Wang, 2013, Clonal chromosomal abnormalities in Philadelphia-negative cells in chronic myeloid leukemia patients treated with nilotinib used in first-line therapy, Ann Hematol, 92, 1625, 10.1007/s00277-013-1816-z

Noens, 2009, Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study, Blood, 113, 5401, 10.1182/blood-2008-12-196543

Wang, 2006, The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia, Haematologica, 91, 235

Landstrom, 2006, Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia, Leuk Lymphoma, 47, 2055, 10.1080/10428190600783551

Branford, 2003, Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis, Blood, 102, 276, 10.1182/blood-2002-09-2896

Soverini, 2019, Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper, J Hematol Oncol, 12, 131, 10.1186/s13045-019-0815-5

Do, 2020, Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE), Br J Haematol, 189, 303, 10.1111/bjh.16381

Jabbour, 2008, Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors, Blood, 112, 4839, 10.1182/blood-2008-04-149948

Koh, 2006, Pregnancies in patients with chronic myeloid leukemia in the era of imatinib, Int J Hematol, 84, 459, 10.1532/IJH97.A20610

Tsao, 2003, Imatinib mesylate causes hypopigmentation in the skin, Cancer, 98, 2483, 10.1002/cncr.11812

Haggstrom, 1996, Two cases of CML treated with alpha-interferon during second and third trimester of pregnancy with analysis of the drug in the new-born immediately postpartum, Eur J Haematol, 57, 101, 10.1111/j.1600-0609.1996.tb00497.x

Tsao, 2003, Imatinib mesylate causes hypopigmentation in the skin, Cancer, 98, 2483, 10.1002/cncr.11812

Abruzzese, 2014, Tyrosine kinase inhibitors and pregnancy, Mediterr J Hematol Infect Dis, 6, e2014028, 10.4084/mjhid.2014.028

Garg, 2009, The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up, Blood, 114, 4361, 10.1182/blood-2009-05-221531

Deruelle, 2007, The use of low-molecular-weight heparins in pregnancy--how safe are they?, Curr Opin Obstet Gynecol, 19, 573, 10.1097/GCO.0b013e3282f10e33

Quintás-Cardama, 2009, Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure, Cancer, 115, 3935, 10.1002/cncr.24432

Cortes, 2016, Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial, Lancet Haematol, 3, e581, 10.1016/S2352-3026(16)30167-3

Branford, 2019, Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia, Leukemia, 33, 1835, 10.1038/s41375-019-0512-y

Okada, 2018, Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment, Clin Lymphoma Myeloma Leuk, 18, 353, 10.1016/j.clml.2018.03.004

Castagnetti, 2017, The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib, Am J Hematol, 92, 797, 10.1002/ajh.24774

Beauverd, 2016, Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series, Haematologica, 101, e182, 10.3324/haematol.2015.139691

Pfirrmann, 2017, No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib, J Cancer Res Clin Oncol, 143, 843, 10.1007/s00432-016-2321-2

Seong, 1995, Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment, Blood, 86, 2343, 10.1182/blood.V86.6.2343.bloodjournal8662343

Kuroiwa, 1998, Interferon-alpha therapy for chronic myelogenous leukemia during pregnancy, Am J Hematol, 59, 101, 10.1002/(SICI)1096-8652(199809)59:1<101::AID-AJH23>3.0.CO;2-D

Beauverd, 2016, Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series, Haematologica, 101, e182, 10.3324/haematol.2015.139691

Soverini, 2015, Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia, Clin Lymphoma Myeloma Leuk, 15, S120, 10.1016/j.clml.2015.02.035

Adnan Awad, 2020, Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia, Blood Adv, 4, 546, 10.1182/bloodadvances.2019000943

Nicolini, 2006, Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP), Leukemia, 20, 1061, 10.1038/sj.leu.2404236

Pye, 2008, The effects of imatinib on pregnancy outcome, Blood, 111, 5505, 10.1182/blood-2007-10-114900

Ghalaut, 2014, Effect of imatinib on male reproductive hormones in BCR-ABL positive CML patients: A preliminary report, J Oncol Pharm Pract, 20, 243, 10.1177/1078155213500686

Ni, 2019, Clinical implications of clonal chromosomal abnormalities in Philadelphia negative cells in CML patients after treated with tyrosine kinase inhibitors, Cancer Genet, 238, 44, 10.1016/j.cancergen.2019.07.008

Sweet, 2018, A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease, Leuk Res, 74, 89, 10.1016/j.leukres.2018.10.002

Melo, 1997, BCR-ABL gene variants, Baillieres Clin Haematol, 10, 203, 10.1016/S0950-3536(97)80003-0

Akard, 2014, Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study, Arch Pathol Lab Med, 138, 1186, 10.5858/arpa.2013-0584-OA

Annunziata, 2020, Current strategies and future directions to achieve deep molecular response and treatment-free remission in chronic myeloid leukemia, Front Oncol, 10, 883, 10.3389/fonc.2020.00883

Kuwabara, 2010, Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response, Blood, 116, 1014, 10.1182/blood-2010-04-280206

Langabeer, 2012, Chronic myeloid leukemia with e19a2 BCR-ABL1 transcripts and marked thrombocytosis: the role of molecular monitoring, Case Rep Hematol, 2012, 458716

Iurlo, 2018, Low-dose ponatinib in intolerant chronic myeloid leukemia patients: a safe and effective option, Clin Drug Investig, 38, 475, 10.1007/s40261-018-0623-7

Lipton, 1996, Alpha-interferon and pregnancy in a patient with CML, Hematol Oncol, 14, 119, 10.1002/(SICI)1099-1069(199609)14:3<119::AID-HON576>3.0.CO;2-Q

Lima, 2011, Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond, Cancer, 117, 1245, 10.1002/cncr.25678

Soverini, 2009, Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors, Blood, 114, 2168, 10.1182/blood-2009-01-197186

Sakurai, 2019, Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia, Int J Hematol, 109, 292, 10.1007/s12185-019-02596-z

Ault, 2006, Pregnancy among patients with chronic myeloid leukemia treated with imatinib, J Clin Oncol, 24, 1204, 10.1200/JCO.2005.04.6557

Branford, 2018, Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease, Blood, 132, 948, 10.1182/blood-2018-02-832253

Cortes, 2007, Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure, Cancer, 110, 2000, 10.1002/cncr.23006

Cortes, 2007, Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib, Cancer, 110, 1295, 10.1002/cncr.22901

Soverini, 2015, Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia, Clin Lymphoma Myeloma Leuk, 15, S120, 10.1016/j.clml.2015.02.035

Massimino, 2018, Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia, Mol Cancer, 17, 56, 10.1186/s12943-018-0805-1

Ross, 2018, Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells, Leukemia, 32, 2572, 10.1038/s41375-018-0264-0

O’Dwyer, 2004, Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate, Blood, 103, 451, 10.1182/blood-2003-02-0371

van Leeuwen, 2014, Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective, Lancet Oncol, 15, e315, 10.1016/S1470-2045(13)70579-5

Assunção, 2019, Cardiovascular risk and cardiovascular events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors, Clin Lymphoma Myeloma Leuk, 19, 162, 10.1016/j.clml.2018.12.004

Deininger, 2007, The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells, Cancer, 110, 1509, 10.1002/cncr.22936

Chelysheva, Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and literature review, Mediterr J Hematol Infect Dis

Siegel, 2020, Cancer statistics, 2020, CA Cancer J Clin, 70, 7, 10.3322/caac.21590

Khorashad, 2008, Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression, J Clin Oncol, 26, 4806, 10.1200/JCO.2008.16.9953

Sheng, 2019, Occurrence of chromosomal abnormalities in Philadelphia chromosome-negative metaphases in patients with chronic-phase chronic myeloid leukemia undergoing TKI treatments, Leuk Lymphoma, 60, 3503, 10.1080/10428194.2019.1636984

Branford, 2014, Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline, Blood, 124, 511, 10.1182/blood-2014-03-566323

Hanfstein, 2014, Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib, Leukemia, 28, 1988, 10.1038/leu.2014.153

Koh, 2006, Pregnancies in patients with chronic myeloid leukemia in the era of imatinib, Int J Hematol, 84, 459, 10.1532/IJH97.A20610

Pagani, Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia [published online June 6, 2020], Leuk Lymphoma

Hanfstein, 2012, Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML), Leukemia, 26, 2096, 10.1038/leu.2012.85

Ilander, 2017, Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia, Leukemia, 31, 1108, 10.1038/leu.2016.360

Yood, 2012, Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia, Curr Med Res Opin, 28, 213, 10.1185/03007995.2011.649849

Soverini, 2014, Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia, Leuk Res, 38, 10, 10.1016/j.leukres.2013.09.011

Branford, 2004, Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations, Blood, 104, 2926, 10.1182/blood-2004-03-1134

Fabarius, 2007, Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure, Haematologica, 92, 834, 10.3324/haematol.11064

Ali, 2004, Successful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with leukapheresis during pregnancy: a case report and review of the literature, Jpn J Clin Oncol, 34, 215, 10.1093/jjco/hyh038

Etienne, 2017, Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia, J Clin Oncol, 35, 298, 10.1200/JCO.2016.68.2914

Cortes, 2018, Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial, J Clin Oncol, 36, 231, 10.1200/JCO.2017.74.7162

Rea, 2017, Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study, Blood, 129, 846, 10.1182/blood-2016-09-742205

Giles, 2013, Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study, Leukemia, 27, 107, 10.1038/leu.2012.181

Thielen, 2013, Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON), Eur J Cancer, 49, 3242, 10.1016/j.ejca.2013.06.018

Feldman, 2003, The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate, Exp Hematol, 31, 702, 10.1016/S0301-472X(03)00176-0

Kimura, 2020, Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial, Lancet Haematol, 7, e218, 10.1016/S2352-3026(19)30235-2

Cortes, 2013, Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors, Am J Hematol, 88, 350, 10.1002/ajh.23408

Davies, 2009, Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters, Leukemia, 23, 1999, 10.1038/leu.2009.166

Nazha, 2013, Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months, Haematologica, 98, 1686, 10.3324/haematol.2013.090282

Soverini, 2006, Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia, Clin Cancer Res, 12, 7374, 10.1158/1078-0432.CCR-06-1516

Cortes, 2018, Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial, Blood, 132, 393, 10.1182/blood-2016-09-739086

Ault, 2006, Pregnancy among patients with chronic myeloid leukemia treated with imatinib, J Clin Oncol, 24, 1204, 10.1200/JCO.2005.04.6557

Langabeer, 2015, Standardized molecular monitoring for variant BCR-ABL1 transcripts in chronic myeloid leukemia, Arch Pathol Lab Med, 139, 969, 10.5858/arpa.2014-0522-LE

Garg, 2009, The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up, Blood, 114, 4361, 10.1182/blood-2009-05-221531

Saussele, 2018, Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV, Leukemia, 32, 1222, 10.1038/s41375-018-0055-7

Yeung, 2015, TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets, Blood, 125, 915, 10.1182/blood-2014-07-590315

Iurlo, 2018, Low-dose ponatinib in intolerant chronic myeloid leukemia patients: a safe and effective option, Clin Drug Investig, 38, 475, 10.1007/s40261-018-0623-7

Kim, 2018, Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study, Ann Hematol, 97, 1357, 10.1007/s00277-018-3295-8

Soverini, 2014, Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia, Leuk Res, 38, 10, 10.1016/j.leukres.2013.09.011

Iriyama, 2015, Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group, Am J Hematol, 90, 282, 10.1002/ajh.23923

Russell, 2007, Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk, J Perinatol, 27, 241, 10.1038/sj.jp.7211665

Marin, 2009, Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?, Br J Haematol, 145, 373, 10.1111/j.1365-2141.2009.07646.x

Ghalaut, 2014, Effect of imatinib on male reproductive hormones in BCR-ABL positive CML patients: A preliminary report, J Oncol Pharm Pract, 20, 243, 10.1177/1078155213500686

White, 2006, OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib, Blood, 108, 697, 10.1182/blood-2005-11-4687

Mahon, 2010, Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial, Lancet Oncol, 11, 1029, 10.1016/S1470-2045(10)70233-3

Marin, 2003, Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses, Blood, 102, 2702, 10.1182/blood-2003-06-2042

Caocci, 2019, Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention, Int J Cardiol, 288, 124, 10.1016/j.ijcard.2019.04.051

Deininger, 2016, Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients, Blood, 127, 703, 10.1182/blood-2015-08-660977

Pye, 2008, The effects of imatinib on pregnancy outcome, Blood, 111, 5505, 10.1182/blood-2007-10-114900

Salem, 2019, Imatinib treatments have long-term impact on placentation and embryo survival, Sci Rep, 9, 2535, 10.1038/s41598-019-39134-0

Cortes, 2007, Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure, Cancer, 110, 2000, 10.1002/cncr.23006

Baldazzi, 2009, Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy, Leuk Res, 33, e218, 10.1016/j.leukres.2009.05.010

Kuroiwa, 1998, Interferon-alpha therapy for chronic myelogenous leukemia during pregnancy, Am J Hematol, 59, 101, 10.1002/(SICI)1096-8652(199809)59:1<101::AID-AJH23>3.0.CO;2-D

Müller, 2009, Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations, Blood, 114, 4944, 10.1182/blood-2009-04-214221

Hoffmann, 2015, The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries, Leukemia, 29, 1336, 10.1038/leu.2015.73

Stella, 2019, Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib, In Vivo, 33, 1593, 10.21873/invivo.11641

Dewald, 1998, Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia, Blood, 91, 3357, 10.1182/blood.V91.9.3357

Shanmuganathan, 2018, Molecular monitoring in CML: how deep? How often? How should it influence therapy?, Hematology (Am Soc Hematol Educ Program), 2018, 168, 10.1182/asheducation-2018.1.168

Serpa, 2010, Efficacy and tolerability after unusually low doses of dasatinib in chronic myeloid leukemia patients intolerant to standard-dose dasatinib therapy, Clin Med Insights Oncol, 4, 155, 10.4137/CMO.S6413

Staley, 2018, Management of chronic myeloid leukemia in the setting of pregnancy: when is leukocytapheresis appropriate? A case report and review of the literature, Transfusion, 58, 456, 10.1111/trf.14448

Jabbour, 2011, Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?, J Clin Oncol, 29, 4260, 10.1200/JCO.2011.36.0693

Jabbour, 2007, Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase, Blood, 110, 2991, 10.1182/blood-2007-01-070045

Hasford, 1998, A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa, J Natl Cancer Inst, 90, 850, 10.1093/jnci/90.11.850

Fabarius, 2015, Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML, Ann Hematol, 94, 2015, 10.1007/s00277-015-2494-9

Sawyers, 1999, Chronic myeloid leukemia, N Engl J Med, 340, 1330, 10.1056/NEJM199904293401706

James, 2008, Aspirin and reproductive outcomes, Obstet Gynecol Surv, 63, 49, 10.1097/OGX.0b013e31815e8731

Lipton, 1996, Alpha-interferon and pregnancy in a patient with CML, Hematol Oncol, 14, 119, 10.1002/(SICI)1099-1069(199609)14:3<119::AID-HON576>3.0.CO;2-Q

Schmidt, 2014, Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status, Leukemia, 28, 2292, 10.1038/leu.2014.272

Quintás-Cardama, 2009, Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia, Blood, 114, 261, 10.1182/blood-2008-09-180604

Hochhaus, 2009, Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia, Leukemia, 23, 1054, 10.1038/leu.2009.38

Wang, 2016, Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy, Blood, 127, 2742, 10.1182/blood-2016-01-690230

Hughes, 2010, Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS), Blood, 116, 3758, 10.1182/blood-2010-03-273979

Baccarani, 2014, Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study, Int J Hematol, 99, 616, 10.1007/s12185-014-1566-2

Xue, 2019, Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts, Leuk Lymphoma, 60, 3051, 10.1080/10428194.2019.1607329

Burmeister, 2008, A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts, Leuk Res, 32, 579, 10.1016/j.leukres.2007.08.017

Fugazza, 2004, Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate, J Exp Clin Cancer Res, 23, 295

Faderl, 1999, The biology of chronic myeloid leukemia, N Engl J Med, 341, 164, 10.1056/NEJM199907153410306

Grossmann, 2011, A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases, Leukemia, 25, 557, 10.1038/leu.2010.298

Hoffmann, 2017, Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia, J Cancer Res Clin Oncol, 143, 1311, 10.1007/s00432-017-2385-7

Bumm, 2003, Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority, Blood, 101, 1941, 10.1182/blood-2002-07-2053

Bergeron, 2007, Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series, Am J Respir Crit Care Med, 176, 814, 10.1164/rccm.200705-715CR

Fadilah, 2002, Successful treatment of chronic myeloid leukemia during pregnancy with hydroxyurea, Leukemia, 16, 1202, 10.1038/sj.leu.2402494

Caocci, 2019, Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart, Hematol Oncol, 37, 296, 10.1002/hon.2606

Kim, 2014, Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors, Haematologica, 99, 1191, 10.3324/haematol.2013.096776

Cornelison, 2012, Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner, J Support Oncol, 10, 14, 10.1016/j.suponc.2011.08.001

Aichberger, 2011, Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML, Am J Hematol, 86, 533, 10.1002/ajh.22037

Cortes, 2016, Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial, J Clin Oncol, 34, 2333, 10.1200/JCO.2015.64.8899

Mori, 2015, Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study, Am J Hematol, 90, 910, 10.1002/ajh.24120

Cortes, 2016, Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: the ENRICH Study, Clin Lymphoma Myeloma Leuk, 16, 286, 10.1016/j.clml.2016.02.002

Tokuhira, 2018, Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, Med Oncol, 35, 38, 10.1007/s12032-018-1093-8

Soverini, 2019, Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper, J Hematol Oncol, 12, 131, 10.1186/s13045-019-0815-5

Terre, 2004, Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia, Leukemia, 18, 1340, 10.1038/sj.leu.2403399

Radich, 2006, Gene expression changes associated with progression and response in chronic myeloid leukemia, Proc Natl Acad Sci USA, 103, 2794, 10.1073/pnas.0510423103

Hughes, 2019, Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia, Haematologica, 104, 93, 10.3324/haematol.2018.188987

Saussele, 2018, Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial, Lancet Oncol, 19, 747, 10.1016/S1470-2045(18)30192-X

Westerweel, 2019, New approaches and treatment combinations for the management of chronic myeloid leukemia, Front Oncol, 9, 665, 10.3389/fonc.2019.00665

Lee, 2016, Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study, Haematologica, 101, 717, 10.3324/haematol.2015.139899

Casavecchia, 2020, Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib, Heart Fail Rev, 25, 447, 10.1007/s10741-020-09926-y

Naqvi, 2018, Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations, Int J Hematol, 107, 689, 10.1007/s12185-018-2422-6

Orlandi, 2012, Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia, Leuk Res, 36, e4, 10.1016/j.leukres.2011.08.007

Madabhavi, 2019, Pregnancy outcomes in chronic myeloid leukemia: a single center experience, J Glob Oncol, 5, 1

Karimata, 2011, Myelodysplastic syndrome with Ph negative monosomy 7 chromosome following transient bone marrow dysplasia during imatinib treatment for chronic myeloid leukemia, Intern Med, 50, 481, 10.2169/internalmedicine.50.4481

Radich, 2006, Gene expression changes associated with progression and response in chronic myeloid leukemia, Proc Natl Acad Sci USA, 103, 2794, 10.1073/pnas.0510423103

Quintas-Cardama, 2004, Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia, Cancer, 100, 2592, 10.1002/cncr.20285

Hochhaus, 2009, Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia, Leukemia, 23, 1054, 10.1038/leu.2009.38

Deininger, 2014, Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia, Br J Haematol, 164, 223, 10.1111/bjh.12618

Kantarjian, 2003, Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia, Clin Cancer Res, 9, 160

Jamieson, 2004, Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML, N Engl J Med, 351, 657, 10.1056/NEJMoa040258

Melo, 1996, The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype, Blood, 88, 2375, 10.1182/blood.V88.7.2375.bloodjournal8872375

Hehlmann, 2014, Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV, J Clin Oncol, 32, 415, 10.1200/JCO.2013.49.9020

Balsat, 2018, Successful pregnancies in patients with BCR-ABL-positive leukemias treated with interferon-alpha therapy during the tyrosine kinase inhibitors era, Eur J Haematol, 101, 774, 10.1111/ejh.13167

Mir, 2015, Simple multiplex RT-PCR for identifying common fusion BCR-ABL transcript types and evaluation of molecular response of the a2b2 and a2b3 transcripts to Imatinib resistance in north Indian chronic myeloid leukemia patients, Indian J Cancer, 52, 314, 10.4103/0019-509X.176741

Deininger, 2016, Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients, Blood, 127, 703, 10.1182/blood-2015-08-660977

Jain, 2016, Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors, Blood, 127, 1269, 10.1182/blood-2015-10-674242

Issa, 2017, Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment, Blood, 130, 2084, 10.1182/blood-2017-07-792143

Soverini, 2016, In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants, BMC Cancer, 16, 572, 10.1186/s12885-016-2635-0

Branford, 2019, Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia, Leukemia, 33, 1835, 10.1038/s41375-019-0512-y

Palani, 2015, Managing pregnancy in chronic myeloid leukaemia, Ann Hematol, 94, S167, 10.1007/s00277-015-2317-z

Cortes, 2018, Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial, J Clin Oncol, 36, 231, 10.1200/JCO.2017.74.7162

Melo, 1997, BCR-ABL gene variants, Baillieres Clin Haematol, 10, 203, 10.1016/S0950-3536(97)80003-0

Clark, 2019, De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial, Lancet Haematol, 6, e375, 10.1016/S2352-3026(19)30094-8

Ross, 2018, Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study, J Cancer Res Clin Oncol, 144, 945, 10.1007/s00432-018-2604-x

Sokal, 1984, Prognostic discrimination in “good-risk” chronic granulocytic leukemia, Blood, 63, 789, 10.1182/blood.V63.4.789.789

Pagani, Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia [published online June 6, 2020], Leuk Lymphoma

Cortes, 2015, The impact of dasatinib on pregnancy outcomes, Am J Hematol, 90, 1111, 10.1002/ajh.24186

Cross, 2012, Standardized definitions of molecular response in chronic myeloid leukemia, Leukemia, 26, 2172, 10.1038/leu.2012.104

Shah, 2020, Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study, Leuk Lymphoma, 61, 650, 10.1080/10428194.2019.1675879

Faderl, 1999, The biology of chronic myeloid leukemia, N Engl J Med, 341, 164, 10.1056/NEJM199907153410306

Quintás-Cardama, 2008, Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia, Clin Lymphoma Myeloma, 8, S82, 10.3816/CLM.2008.s.003

Baykal, 2000, Use of hydroxyurea and alpha-interferon in chronic myeloid leukemia during pregnancy: a case report, Eur J Gynaecol Oncol, 21, 89

Massimino, 2018, Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia, Mol Cancer, 17, 56, 10.1186/s12943-018-0805-1

Thauvin-Robinet, 2001, Exposure to hydroxyurea during pregnancy: a case series, Leukemia, 15, 1309, 10.1038/sj.leu.2402168

Abruzzese, 2014, Tyrosine kinase inhibitors and pregnancy, Mediterr J Hematol Infect Dis, 6, e2014028, 10.4084/mjhid.2014.028

Ramasamy, 2007, Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy, Br J Haematol, 137, 374, 10.1111/j.1365-2141.2007.06542.x

Breccia, 2008, Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases, Leuk Res, 32, 519, 10.1016/j.leukres.2007.07.022

Hughes, 2009, Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase, J Clin Oncol, 27, 4204, 10.1200/JCO.2009.21.8230

Grossmann, 2011, A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases, Leukemia, 25, 557, 10.1038/leu.2010.298

Montani, 2012, Pulmonary arterial hypertension in patients treated by dasatinib, Circulation, 125, 2128, 10.1161/CIRCULATIONAHA.111.079921

Shanmuganathan, 2018, Molecular monitoring in CML: how deep? How often? How should it influence therapy?, Hematology (Am Soc Hematol Educ Program), 2018, 168, 10.1182/asheducation-2018.1.168

Feldman, 2003, The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate, Exp Hematol, 31, 702, 10.1016/S0301-472X(03)00176-0

Hiwase, 2018, Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the phase IIIb ENESTswift study, Leuk Res, 67, 109, 10.1016/j.leukres.2018.02.013

Navarro, 2007, Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome, Am J Hematol, 82, 849, 10.1002/ajh.20859

Tefferi, 2011, Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia, Am J Hematol, 86, 610, 10.1002/ajh.22051

Douet-Guilbert, 2004, Interphase FISH for follow-up of Philadelphia chromosome-positive chronic myeloid leukemia treatment, Anticancer Res, 24, 2535

Sawyers, 1999, Chronic myeloid leukemia, N Engl J Med, 340, 1330, 10.1056/NEJM199904293401706

Press, 2007, A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response, Clin Cancer Res, 13, 6136, 10.1158/1078-0432.CCR-07-1112

Hanfstein, 2012, Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML), Leukemia, 26, 2096, 10.1038/leu.2012.85

Kizilors, 2019, Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study, Lancet Haematol, 6, e276, 10.1016/S2352-3026(19)30027-4

de Lavallade, 2008, Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis, J Clin Oncol, 26, 3358, 10.1200/JCO.2007.15.8154

Reinhold, 2003, FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib, Leukemia, 17, 1925, 10.1038/sj.leu.2403077

Bouchet, 2013, Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory, Fundam Clin Pharmacol, 27, 690, 10.1111/fcp.12007

Santos, 2011, Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib, Cancer, 117, 982, 10.1002/cncr.25533

Hasford, 1998, A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa, J Natl Cancer Inst, 90, 850, 10.1093/jnci/90.11.850

Kantarjian, 2009, Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase, Cancer, 115, 551, 10.1002/cncr.24066

Branford, 2006, Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia, Leukemia, 20, 1925, 10.1038/sj.leu.2404388

Verma, 2009, Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance, Blood, 114, 2232, 10.1182/blood-2009-02-204693

Ross, 2018, Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells, Leukemia, 32, 2572, 10.1038/s41375-018-0264-0

Mahon, 2008, Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression, Cancer Res, 68, 9809, 10.1158/0008-5472.CAN-08-1008

Branford, 2008, Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials, Blood, 112, 3330, 10.1182/blood-2008-04-150680

Jabbour, 2011, The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors, Blood, 118, 4541, 10.1182/blood-2011-04-348110

Hoffmann, 2015, The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries, Leukemia, 29, 1336, 10.1038/leu.2015.73

Zabriskie, 2014, BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia, Cancer Cell, 26, 428, 10.1016/j.ccr.2014.07.006

Berman, 2013, Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors, Leuk Res, 37, 790, 10.1016/j.leukres.2013.02.005

Testoni, 2009, Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP, Blood, 114, 4939, 10.1182/blood-2009-07-229864

Cortes, 2016, Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib, Am J Hematol, 91, 1206, 10.1002/ajh.24536

Hehlmann, 2017, Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants, Leukemia, 31, 2398, 10.1038/leu.2017.253

Press, 2009, Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib, Blood, 114, 2598, 10.1182/blood-2008-08-173674

Aleem, 2009, Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia, Hematol Oncol Stem Cell Ther, 2, 358, 10.1016/S1658-3876(09)50026-X

Marin, 2012, Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors, J Clin Oncol, 30, 232, 10.1200/JCO.2011.38.6565

Breccia, 2008, Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases, Leuk Res, 32, 519, 10.1016/j.leukres.2007.07.022

Neelakantan, 2013, Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies, Blood, 121, 2739, 10.1182/blood-2012-11-466037

Kantarjian, 2009, Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response, J Clin Oncol, 27, 3659, 10.1200/JCO.2008.18.6999

Ibrahim, 2011, Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy, Blood, 117, 3733, 10.1182/blood-2010-10-309807

Cortes, 2016, Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial, J Clin Oncol, 34, 2333, 10.1200/JCO.2015.64.8899

Casavecchia, 2020, Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib, Heart Fail Rev, 25, 447, 10.1007/s10741-020-09926-y

Berman, 2006, Altered bone and mineral metabolism in patients receiving imatinib mesylate, N Engl J Med, 354, 2006, 10.1056/NEJMoa051140

Al Bahar, 2004, Pregnancy in chronic myeloid leukemia patients treated with alpha interferon, Int J Gynaecol Obstet, 85, 281, 10.1016/j.ijgo.2003.11.014

Osorio, 2018, Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?, Ann Hematol, 97, 2089, 10.1007/s00277-018-3413-7

Ali, 2009, Imatinib use during pregnancy and breast feeding: a case report and review of the literature, Arch Gynecol Obstet, 280, 169, 10.1007/s00404-008-0861-7

Sokal, 1984, Prognostic discrimination in “good-risk” chronic granulocytic leukemia, Blood, 63, 789, 10.1182/blood.V63.4.789.789

Alhuraiji, 2018, Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors, Am J Hematol, 93, 84, 10.1002/ajh.24943

Fadilah, 2002, Successful treatment of chronic myeloid leukemia during pregnancy with hydroxyurea, Leukemia, 16, 1202, 10.1038/sj.leu.2402494

Berman, 2013, Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors, Leuk Res, 37, 790, 10.1016/j.leukres.2013.02.005

Porkka, 2010, Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion, Cancer, 116, 377, 10.1002/cncr.24734

Bouchet, 2013, Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory, Fundam Clin Pharmacol, 27, 690, 10.1111/fcp.12007

Wang, 2015, Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis, J Hematol Oncol, 8, 32, 10.1186/s13045-015-0128-2

Lasica, 2019, The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia, Leuk Lymphoma, 60, 1796, 10.1080/10428194.2018.1551533

Stella, 2019, Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib, In Vivo, 33, 1593, 10.21873/invivo.11641

Wu, 2010, Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia, Curr Med Res Opin, 26, 2861, 10.1185/03007995.2010.533648

Petiti, 2020, Novel multiplex droplet digital PCR assays to mnitor minimal residual disease in chronic myeloid leukemia patients showing atypical BCR-ABL1 transcripts, J Clin Med, 9, 1457, 10.3390/jcm9051457

Soverini, 2007, Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain, Haematologica, 92, 401, 10.3324/haematol.10822

Thauvin-Robinet, 2001, Exposure to hydroxyurea during pregnancy: a case series, Leukemia, 15, 1309, 10.1038/sj.leu.2402168

Khoury, 2012, Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure, Blood, 119, 3403, 10.1182/blood-2011-11-390120

Hochhaus, 2017, Long-term outcomes of imatinib treatment of chronic myeloid leukemia, N Engl J Med, 376, 917, 10.1056/NEJMoa1609324

Ramasamy, 2007, Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy, Br J Haematol, 137, 374, 10.1111/j.1365-2141.2007.06542.x

Efficace, 2013, Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib, Leukemia, 27, 1511, 10.1038/leu.2013.51

Hughes, 2006, Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results, Blood, 108, 28, 10.1182/blood-2006-01-0092

Ibrahim, 2011, Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy, Blood, 117, 3733, 10.1182/blood-2010-10-309807

van Leeuwen, 2014, Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective, Lancet Oncol, 15, e315, 10.1016/S1470-2045(13)70579-5

Baccarani, 2019, The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview, Leukemia, 33, 1173, 10.1038/s41375-018-0341-4

Hiwase, 2008, Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications, Clin Cancer Res, 14, 3881, 10.1158/1078-0432.CCR-07-5095

Xue, 2019, Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts, Leuk Lymphoma, 60, 3051, 10.1080/10428194.2019.1607329

James, 2008, Aspirin and reproductive outcomes, Obstet Gynecol Surv, 63, 49, 10.1097/OGX.0b013e31815e8731

Quintás-Cardama, 2008, Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia, Clin Lymphoma Myeloma, 8, S82, 10.3816/CLM.2008.s.003

Wang, 2015, Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors, Blood, 126, 1699, 10.1182/blood-2015-05-646489

Cervantes, 2010, Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group, Haematologica, 95, 1317, 10.3324/haematol.2009.021154

Burmeister, 2008, A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts, Leuk Res, 32, 579, 10.1016/j.leukres.2007.08.017

Cortes, 2012, Ponatinib in refractory Philadelphia chromosome-positive leukemias, N Engl J Med, 367, 2075, 10.1056/NEJMoa1205127

Quintás-Cardama, 2009, Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia, Blood, 114, 261, 10.1182/blood-2008-09-180604

Cross, 2009, Standardisation of molecular monitoring for chronic myeloid leukaemia, Best Pract Res Clin Haematol, 22, 355, 10.1016/j.beha.2009.04.001

Naqvi, 2020, Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia, Cancer, 126, 67, 10.1002/cncr.32504

Fugazza, 2004, Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate, J Exp Clin Cancer Res, 23, 295

Salem, 2019, Imatinib treatments have long-term impact on placentation and embryo survival, Sci Rep, 9, 2535, 10.1038/s41598-019-39134-0

Ercaliskan, 2018, The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia, Cancer, 124, 3806, 10.1002/cncr.31408

Branford, 2014, Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline, Blood, 124, 511, 10.1182/blood-2014-03-566323

Melo, 1996, The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype, Blood, 88, 2375, 10.1182/blood.V88.7.2375.bloodjournal8872375

Kantarjian, 2009, Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase, Cancer, 115, 551, 10.1002/cncr.24066

Verma, 2010, Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy, Cancer, 116, 2673, 10.1002/cncr.25015

Yeung, 2015, TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets, Blood, 125, 915, 10.1182/blood-2014-07-590315

Baccarani, 2019, The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview, Leukemia, 33, 1173, 10.1038/s41375-018-0341-4

Crampe, 2017, Characterization of a novel variant BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring, Hematol Oncol Stem Cell Ther, 10, 85, 10.1016/j.hemonc.2016.02.002

Fabarius, 2011, Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV, Blood, 118, 6760, 10.1182/blood-2011-08-373902

Thomas, 2004, Active transport of imatinib into and out of cells: implications for drug resistance, Blood, 104, 3739, 10.1182/blood-2003-12-4276

Shah, 2016, Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034, Am J Hematol, 91, 869, 10.1002/ajh.24423

Mahon, 2018, Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study, Ann Intern Med, 168, 461, 10.7326/M17-1094

Chelysheva, Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and literature review, Mediterr J Hematol Infect Dis

Bose, 1998, The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease, Blood, 92, 3362, 10.1182/blood.V92.9.3362

Cross, 2012, Standardized definitions of molecular response in chronic myeloid leukemia, Leukemia, 26, 2172, 10.1038/leu.2012.104

Kim, 2017, Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy, Blood, 129, 38, 10.1182/blood-2016-04-708560

Biernaux, 1995, Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals, Blood, 86, 3118, 10.1182/blood.V86.8.3118.3118

Ercaliskan, 2018, The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia, Cancer, 124, 3806, 10.1002/cncr.31408

García-Gutiérrez, 2019, Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients, Ann Hematol, 98, 321, 10.1007/s00277-018-3507-2

Qin, 2018, Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre, Br J Haematol, 182, 693, 10.1111/bjh.15453

Saussele, 2018, Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV, Leukemia, 32, 1222, 10.1038/s41375-018-0055-7

Kantarjian, 2003, Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia, Blood, 101, 473, 10.1182/blood-2002-05-1451

Deruelle, 2007, The use of low-molecular-weight heparins in pregnancy--how safe are they?, Curr Opin Obstet Gynecol, 19, 573, 10.1097/GCO.0b013e3282f10e33

Rousselot, 2014, Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease, J Clin Oncol, 32, 424, 10.1200/JCO.2012.48.5797

Cortes, 2015, The impact of dasatinib on pregnancy outcomes, Am J Hematol, 90, 1111, 10.1002/ajh.24186

Jamieson, 2004, Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML, N Engl J Med, 351, 657, 10.1056/NEJMoa040258

Cirmi, 2020, Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse event reporting system database (FAERS), Cancers (Basel), 12, 826, 10.3390/cancers12040826

Pfirrmann, 2016, Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia, Leukemia, 30, 48, 10.1038/leu.2015.261

Druker, 2006, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia, N Engl J Med, 355, 2408, 10.1056/NEJMoa062867

Mitelman, 1993, The cytogenetic scenario of chronic myeloid leukemia, Leuk Lymphoma, 11, 11, 10.3109/10428199309047856

Cortes, 2012, Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation, Blood, 120, 2573, 10.1182/blood-2012-03-415307

Burchert, 2010, Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia, J Clin Oncol, 28, 1429, 10.1200/JCO.2009.25.5075

Yood, 2012, Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia, Curr Med Res Opin, 28, 213, 10.1185/03007995.2011.649849

Russell, 2007, Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk, J Perinatol, 27, 241, 10.1038/sj.jp.7211665

Ali, 2009, Imatinib use during pregnancy and breast feeding: a case report and review of the literature, Arch Gynecol Obstet, 280, 169, 10.1007/s00404-008-0861-7

Hanfstein, 2014, Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib, Haematologica, 99, 1441, 10.3324/haematol.2013.096537

Siegel, 2020, Cancer statistics, 2020, CA Cancer J Clin, 70, 7, 10.3322/caac.21590

Mahon, 2008, Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression, Cancer Res, 68, 9809, 10.1158/0008-5472.CAN-08-1008

Press, 2009, Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib, Blood, 114, 2598, 10.1182/blood-2008-08-173674

Neelakantan, 2013, Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies, Blood, 121, 2739, 10.1182/blood-2012-11-466037

Medina, 2003, Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase, Cancer, 98, 1905, 10.1002/cncr.11729

Gong, 2017, Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia, Blood Cancer J, 7, e583, 10.1038/bcj.2017.62

Cortes, 2012, Ponatinib in refractory Philadelphia chromosome-positive leukemias, N Engl J Med, 367, 2075, 10.1056/NEJMoa1205127

Abruzzese, 2019, Pregnancy management in CML patients: to teat or not to treat? Report of 224 outcomes of the European Leukemia Net (ELN) Database, Blood, 134, 498, 10.1182/blood-2019-124430

Picard, 2007, Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia, Blood, 109, 3496, 10.1182/blood-2006-07-036012

Douet-Guilbert, 2004, Interphase FISH for follow-up of Philadelphia chromosome-positive chronic myeloid leukemia treatment, Anticancer Res, 24, 2535

Jabbour, 2008, Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy, Blood, 112, 53, 10.1182/blood-2007-11-123950

Etienne, 2017, Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia, J Clin Oncol, 35, 298, 10.1200/JCO.2016.68.2914

Soverini, 2020, Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study, Blood, 135, 534, 10.1182/blood.2019002969

Arun, 2017, Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients, Int J Lab Hematol, 39, 235, 10.1111/ijlh.12616

Baykal, 2000, Use of hydroxyurea and alpha-interferon in chronic myeloid leukemia during pregnancy: a case report, Eur J Gynaecol Oncol, 21, 89

Ilander, 2017, Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia, Leukemia, 31, 1108, 10.1038/leu.2016.360

Mitelman, 1993, The cytogenetic scenario of chronic myeloid leukemia, Leuk Lymphoma, 11, 11, 10.3109/10428199309047856

Khoury, 2012, Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure, Blood, 119, 3403, 10.1182/blood-2011-11-390120

White, 2012, Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib, Haematologica, 97, 907, 10.3324/haematol.2011.056457

Nicolini, 2007, Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation, Haematologica, 92, 1238, 10.3324/haematol.11369

Jabbour, 2009, Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy, Blood, 113, 2154, 10.1182/blood-2008-04-154344

Cross, 2009, Standardisation of molecular monitoring for chronic myeloid leukaemia, Best Pract Res Clin Haematol, 22, 355, 10.1016/j.beha.2009.04.001

Nazha, 2013, Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months, Haematologica, 98, 1686, 10.3324/haematol.2013.090282

Kantarjian, 2003, Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia, Blood, 101, 473, 10.1182/blood-2002-05-1451

Shah, 2016, Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034, Am J Hematol, 91, 869, 10.1002/ajh.24423

Jain, 2016, Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors, Blood, 127, 1269, 10.1182/blood-2015-10-674242

Hochhaus, 2016, Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial, Leukemia, 30, 1044, 10.1038/leu.2016.5

Barkoulas, 2018, Experience with dasatinib and nilotinib use in pregnancy, J Oncol Pharm Pract, 24, 121, 10.1177/1078155217692399

Qin, 2018, Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre, Br J Haematol, 182, 693, 10.1111/bjh.15453

Naqvi, 2020, Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia, Cancer, 126, 67, 10.1002/cncr.32504

Fabarius, 2015, Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML, Ann Hematol, 94, 2015, 10.1007/s00277-015-2494-9

Giles, 2013, Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis, Leukemia, 27, 1310, 10.1038/leu.2013.69

Montani, 2012, Pulmonary arterial hypertension in patients treated by dasatinib, Circulation, 125, 2128, 10.1161/CIRCULATIONAHA.111.079921

Jain, 2019, Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs, Blood Adv, 3, 851, 10.1182/bloodadvances.2018025874

Naqvi, 2018, Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations, Int J Hematol, 107, 689, 10.1007/s12185-018-2422-6

Cortes, 2016, Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib, Am J Hematol, 91, 1206, 10.1002/ajh.24536

Bennour, 2012, Comprehensive analysis of BCR/ABL variants in chronic myeloid leukemia patients using multiplex RT-PCR, Clin Lab, 58, 433

Togasaki, 2017, Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia, Blood Cancer J, 7, e559, 10.1038/bcj.2017.36

Gong, 2017, Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia, Blood Cancer J, 7, e583, 10.1038/bcj.2017.62

Marin, 2010, Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib, J Clin Oncol, 28, 2381, 10.1200/JCO.2009.26.3087

Verma, 2009, Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance, Blood, 114, 2232, 10.1182/blood-2009-02-204693

Bidet, 2019, Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia, Haematologica, 104, 1150, 10.3324/haematol.2018.208801

Wang, 2015, Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors, Blood, 126, 1699, 10.1182/blood-2015-05-646489

Bergeron, 2007, Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series, Am J Respir Crit Care Med, 176, 814, 10.1164/rccm.200705-715CR

Cortes, 2003, Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy, Blood, 101, 3794, 10.1182/blood-2002-09-2790